Figure 1.

Class IIa HDAC catalytic domain inhibition does not suppress agonist-dependent hypertrophy of cardiomyocytes. A, NRVMs were treated with vehicle control (Veh; DMSO, 0.1% final concentration) or TMP195 (3 μm) in the absence or presence of phenylephrine (PE, 10 μm) for 48 h. Cells were fixed and analyzed by indirect immunofluorescence with an antibody against sarcomeric α-actinin. Scale bars = 50 μm. B, the cell area was quantified. C–E, quantitative RT-PCR analysis of Nppa, Myh7, and Xirp2 mRNA expression with RNA prepared from parallel plates of NRVMs. For B–E, values represent means + S.E.; *, p < 0.05 versus corresponding conditions but without PE. For B, n = the number of cells quantified. For C–E, n = plates of NRVMs per condition.